SCHEDULE 13G: Deep Track Capital Discloses 6.91% Stake in Maze Therapeutics Inc.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a collective beneficial ownership of 6.91% in Maze Therapeutics Inc.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership in Maze Therapeutics Inc.
• The reporting persons collectively own 3,023,484 shares of Maze Therapeutics Inc. Common Stock.
• This ownership represents 6.91% of the outstanding Common Stock of Maze Therapeutics Inc., based on 43,776,978 shares outstanding as of January 31, 2025.
• The shares are held with shared voting power and shared dispositive power among the reporting persons.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or outlook. It is neutral in tone and content regarding the company's operations.

Positives

• The disclosure of a significant institutional investor like Deep Track Capital holding a stake can be viewed positively by the market, indicating confidence in Maze Therapeutics Inc.

Negatives

• The filing itself does not contain any negative information regarding Maze Therapeutics Inc.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate control-related risks from this specific filing.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Maze Therapeutics Inc.'s future operations or financial performance.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director for Deep Track Biotechnology Master Fund, Ltd., certified that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

The filing indicates a significant investment by a specialized biotechnology fund (Deep Track Biotechnology Master Fund, Ltd.) in Maze Therapeutics Inc., suggesting that Maze Therapeutics operates within the biotechnology sector. This reflects continued investor interest in the biotech industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder can influence investor perception and potentially stock liquidity.
• Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Maze Therapeutics Inc., Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing